Structure and function of VEGF receptors

IUBMB Life

Volumn 61, Issue 9, 2009, Pages 915-922

  Stuttfeld, Edward ^a   Ballmer Hofer, Kurt ^a  

^a PAUL SCHERRER INSTITUTE   (Switzerland)

Author keywords

Angiogenesis; Membrane proteins; Protein structure; Receptor; Signal transduction; Structure; VEGF

Indexed keywords

CYTOKINE; HEPARAN SULFATE; NEUROPILIN; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; DIMERIZATION; HUMAN; HYPOXIA; LIGAND BINDING; LYMPHANGIOGENESIS; NONHUMAN; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CHEMISTRY; PHYSIOLOGY; STRUCTURE ACTIVITY RELATION;

ANIMALS; HUMANS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70350780365     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.234     Document Type: Review

References (96)

1. Gu, J. and Gu, X. (2003) Natural history and functional divergence of protein tyrosine kinases. Gene 317, 49-57. (Pubitemid 37356917)
2. Manning, G., Plowman, G. D., Hunter, T., and Sudarsanam, S. (2002) Evolution of protein kinase signaling from yeast to man. Trends Biochem. Sci. 27, 514-520.
3. Manning, G., Whyte, D. B., Martinez, R., Hunter, T., and Sudarsanam, S. (2002) The protein kinase complement of the human genome. Science 298, 1912-1934. (Pubitemid 35425239)
4. Kostich, M., English, J., Madison, V., Gheyas, F., Wang, L., Qiu, P., Greene, J., and Laz, T. M. (2002) Human members of the eukaryotic protein kinase family. Genome Biol. 3, 43.1-43.12.
5. Hubbard, S. R. and Till, J. H. (2000) Protein tyrosine kinase structure and function. Annu. Rev. Biochem. 69, 373-398.
6. Robinson, D. R., Wu, Y. M., and Lin, S. F. (2000) The protein tyrosine kinase family of the human genome. Oncogene 19, 5548-5557.
7. Grassot, J., Gouy, M., Perriere, G., and Mouchiroud, G. (2006) Origin and molecular evolution of receptor tyrosine kinases with immunoglobulin-like domains. Mol. Biol. Evol. 23, 1232-1241.
8. Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., and Dvorak, H. F. (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983-985.
9. Ferrara, N. (2009) History of discovery: vascular endothelial growth factor. Arterioscler. Thromb. Vasc. Biol. 29, 789-791, PMID: 19164810.
10. Dvorak, H. F. (2006) Discovery of vascular permeability factor (VPF). Exp. Cell Res. 312, 522-526.
11. Ferrara, N. and Henzel, W. J. (1989) Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 161, 851-858.
12. Plouet, J., Schilling, J., and Gospodarowicz, D. (1989) Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells. EMBO J. 8, 3801-3806. (Pubitemid 20016061)
13. Keck, P. J., Hauser, S. D., Krivi, G., Sanzo, K., Warren, T., Feder, J., and Connolly, D. T. (1989) Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246, 1309-1312. (Pubitemid 20066717)
14. Leung, D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V., and Ferrara, N. (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306-1309. (Pubitemid 20066716)
15. Robinson, C. J. and Stringer, S. E. (2001) The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J. Cell Sci. 114, 853-865. (Pubitemid 32273121)
16. Lee, S., Jilani, S. M., Nikolova, G. V., Carpizo, D., and Iruela-Arispe, M. L. (2005) Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J. Cell Biol. 169, 681-691. (Pubitemid 41002860)
17. Harper, S. J. and Bates, D. O. (2008) VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat. Rev. Cancer 8, 880-887.
18. Shibuya, M. (2003) Vascular endothelial growth factor receptor-2: its unique signaling and specific ligand, VEGF-E. Cancer Sci. 94, 751-756.
19. Yamazaki, Y., Matsunaga, Y., Tokunaga, Y., Obayashi, S., Saito, M., and Morita, T. (2009) Snake venom vascular endothelial growth factors (VEGF-Fs) exclusively vary their structures and functions among species. J. Biol. Chem. 284, 9885-9891.
20. Cébe-Suarez, S., Zehnder-Fjällman, A. H., and Ballmer-Hofer, K. (2006) The role of VEGF receptors in angiogenesis; complex partnerships. Cell. Mol. Life Sci. 63, 601-615.
21. Shibuya, M. and Claesson-Welsh, L. (2005) Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp. Cell Res. 312, 549-560.
22. Nagy, J. A., Benjamin, L., Zeng, H., Dvorak, A. M., and Dvorak, H. F. (2008) Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis 11, 109-119.
23. Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., Declercq, C., Pawling, J., Moons, L., Collen, D., Risau, W., and Nagy, A. (1996) Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380, 435-439.
24. Ferrara, N., Carver Moore, K., Chen, H., Dowd, M., Lu, L., O Shea, K. S., Powell, B. L., Hillan, K. J., and Moore, M. W. (1996) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380, 439-442.
25. Shalaby, F., Ho, J., Stanford, W. L., Fischer, K. D., Schuh, A. C., Schwartz, L., Bernstein, A., and Rossant, J. (1997) A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis. Cell 89, 981-990.
26. Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X. F., Breitman, M. L., and Schuh, A. C. (1995) Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376, 62-66.
27. Fong, G. H., Zhang, L., Bryce, D. M., and Peng, J. (1999) Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development 126, 3015-3025. (Pubitemid 29355693)
28. Fong, G. H., Klingensmith, J., Wood, C. R., Rossant, J., and Breitman, M. L. (1996) Regulation of flt-1 expression during mouse embryogenesis suggests a role in the establishment of vascular endothelium. Dev. Dyn. 207, 1-10.
29. Fong, G. H., Rossant, J., Gertsenstein, M., and Breitman, M. L. (1995) Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376, 66-70.
30. Ferrara, N. (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25, 581-611.
31. Eichmann, A., Marcelle, C., Breant, C., and Le Douarin, N. M. (1996) Molecular cloning of Quek 1 and 2, two quail vascular endothelial growth factor (VEGF) receptor-like molecules. Gene 174, 3-8. (Pubitemid 26326844)
32. Yamaguchi, S., Iwata, K., and Shibuya, M. (2002) Soluble Flt-1 (Soluble VEGFR-1), a potent natural antiangiogenic molecule in mammals, is phylogenetically conserved in avians. Biochem. Biophys. Res. Commun. 291, 554-559.
33. Thompson, M. A., Ransom, D. G., Pratt, S. J., MacLennan, H., Kieran, M. W., Detrich, H. W. III, Vail, B., Huber, T. L., Paw, B., Brownlie, A. J., Oates, A. C., Fritz, A., Gates, M. A., Amores, A., Bahary, N., Talbot, W. S., Her, H., Beier, D. R., Postlethwait, J. H., and Zon, L. I. (1998) The cloche and spadetail genes differentially affect hematopoiesis and vasculogenesis. Dev. Biol. 197, 248-269.
34. Cleaver, O., Tonissen, K. F., Saha, M. S., and Krieg, P. A. (1997) Neovascularization of the Xenopus embryo. Dev. Dyn. 210, 66-77.
35. Popovici, C., Roubin, R., Coulier, F., Pontarotti, P., and Birnbaum, D. (1999) The family of Caenorhabditis elegans tyrosine kinase receptors: similarities and differences with mammalian receptors. Genome Res. 9, 1026-1039.
36. Heino, T. I., Karpanen, T., Wahlstrom, G., Pulkkinen, M., Eriksson, U., Alitalo, K., and Roos, C. (2001) The Drosophila VEGF receptor homolog is expressed in hemocytes. Mech. Dev. 109, 69-77.
37. Shibuya, M. (2002) Vascular endothelial growth factor receptor family genes: when did the three genes phylogenetically segregate? Biol. Chem. 383, 1573-1579.
38. Bahary, N., Goishi, K., Stuckenholz, C., Weber, G., Leblanc, J., Schafer, C. A., Berman, S. S., Klagsbrun, M., and Zon, L. I. (2007) Duplicate VegfA genes and orthologues of the KDR receptor tyrosine kinase family mediate vascular development in the zebrafish. Blood 110, 3627-3636.
39. Rottbauer, W., Just, S., Wessels, G., Trano, N., Most, P., Katus, H. A., and Fishman, M. C. (2005) VEGF-PLCgamma1 pathway controls cardiac contractility in the embryonic heart. Genes Dev. 19, 1624-1634. (Pubitemid 41003004)
40. Bussmann, J., Bakkers, J., and Schulte-Merker, S. (2007) Early endocardial morphogenesis requires Scl/Tal1. PLoS Genet 3, e140.
41. Bussmann, J., Lawson, N., Zon, L., and Schulte-Merker, S. (2008) Zebrafish VEGF receptors: a guideline to nomenclature. PLoS Genet 4, e1000064.
42. Duchek, P., Somogyi, K., Jekely, G., Beccari, S., and Rorth, P. (2001) Guidance of cell migration by the drosophila pdgf/vegf receptor. Cell 107, 17-26. (Pubitemid 32972034)
43. Cho, N. K., Keyes, L., Johnson, E., Heller, J., Ryner, L., Karim, F., and Krasnow, M. A. (2002) Developmental control of blood cell migration by the drosophila VEGF pathway. Cell 108, 865-876. (Pubitemid 34327536)
44. Schlessinger, J. and Lemmon, M. A. (2003) Sh2 And Ptb domains in tyrosine kinase signaling. Sci. STKE 191, RE12.
45. Wiesmann, C., Muller, Y. A., and de Vos, A. M. (2000) Ligand-binding sites in Ig-like domains of receptor tyrosine kinases. J. Mol. Med. 78, 247-260.
46. Blechman, J. M., Lev, S., Brizzi, M. F., Leitner, O., Pegoraro, L., Givol, D., and Yarden, Y. (1993) Soluble c-kit proteins and antireceptor monoclonal antibodies confine the binding site of the stem cell factor. J. Biol. Chem. 268, 4399-4406.
47. Blechman, J. M. and Yarden, Y. (1995) Structural aspects of receptor dimerization. c-kit as an example. Ann. N Y Acad. Sci. 766, 344-362.
48. Herren, B., Rooney, B., Weyer, K. A., Iberg, N., Schmid, G., and Pech, M. (1993) Dimerization of extracellular domains of platelet-derived growth factor receptors. A revised model of receptor-ligand interaction. J. Biol. Chem. 268, 15088-15095.
49. Fuh, G., Li, B., Crowley, C., Cunningham, B., and Wells, J. A. (1998) Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor. J. Biol. Chem. 273, 11197-11204.
50. Shinkai, A., Ito, M., Anazawa, H., Yamaguchi, S., Shitara, K., and Shibuya, M. (1998) Mapping of the sites involved in ligand association and dissociation at the extracellular domain of the kinase insert domain-containing receptor for vascular endothelial growth factor. J. Biol. Chem. 273, 31283-31288.
51. Shulman, T., Sauer, F. G., Jackman, R. M., Chang, C. N., and Landolfi, N. F. (1997) An antibody reactive with domain 4 of the platelet-derived growth factor beta receptor allows BB binding while inhibiting proliferation by impairing receptor dimerization. J. Biol. Chem. 272, 17400-17404.
52. Plotnikov, A. N., Hubbard, S. R., Schlessinger, J., and Mohammadi, M. (2000) Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity. Cell 101, 413-424.
53. Pellegrini, L., Burke, D. F., von Delft, F., Mulloy, B., and Blundell, T. L. (2000) Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature 407, 1029-1034.
54. Stauber, D. J., DiGabriele, A. D., and Hendrickson, W. A. (2000) Structural interactions of fibroblast growth factor receptor with its ligands. Proc. Natl. Acad. Sci. USA 97, 49-54.
55. Plotnikov, A. N., Schlessinger, J., Hubbard, S. R., and Mohammadi, M. (1999) Structural basis for FGF receptor dimerization and activation. Cell 98, 641-650. (Pubitemid 29418955)
56. Huhtala, M. T., Pentikainen, O. T., and Johnson, M. S. (1999) A dimeric ternary complex of FGFR [correction of FGFR1], heparin and FGF-1 leads to an 'electrostatic sandwich' model for heparin binding. Structure 7, 699-709.
57. Yuzawa, S., Opatowsky, Y., Zhang, Z., Mandiyan, V., Lax, I., and Schlessinger, J. (2007) Structural basis for activation of the receptor tyrosine kinase Kit by stem cell factor. Cell 130, 323-334. (Pubitemid 47081138)
58. Christinger, H. W., Fuh, G., de Vos, A. M., and Wiesmann, C. (2004) The crystal structure of PlGF in complex with domain 2 of VEGFR1. J. Biol. Chem. 279, 10382-10388.
59. Wiesmann, C., Fuh, G., Christinger, H. W., Eigenbrot, C., Wells, J. A., and de Vos, A. M. (1997) Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell 91, 695-704.
60. Li, B., Fuh, G., Meng, G., Xin, X., Gerritsen, M. E., Cunningham, B., and de Vos, A. M. (2000) Receptor-selective variants of human vascular endothelial growth factor. Generation and characterization. J. Biol. Chem. 275, 29823-29828.
61. Yang, Y., Yuzawa, S., and Schlessinger, J. (2008) Contacts between membrane proximal regions of the PDGF receptor ectodomain are required for receptor activation but not for receptor dimerization. Proc. Natl. Acad. Sci. USA 105, 7681-7686.
62. Ruch, C., Skiniotis, G., Steinmetz, M. O., Walz, T., and Ballmer-Hofer, K. (2007) Structure of a VEGF-VEGF receptor complex determined by electron microscopy. Nat. Struct. Mol. Biol. 14, 249-250.
63. Blechman, J. M., Lev, S., Barg, J., Eisenstein, M., Vaks, B., Vogel, Z., Givol, D., and Yarden, Y. (1995) The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction. Cell 80, 103-113.
64. Miyazawa, K., Backstrom, G., Leppanen, O., Persson, C., Wernstedt, C., Hellman, U., Heldin, C. H., and Ostman, A. (1998) Role of immunoglobulin-like domains 2-4 of the platelet-derived growth factor alpha-receptor in ligand-receptor complex assembly. J. Biol. Chem. 273, 25495-25502.
65. Omura, T., Heldin, C. H., and Ostman, A. (1997) Immunoglobulin-like domain 4-mediated receptor-receptor interactions contribute to platelet-derived growth factor-induced receptor dimerization. J. Biol. Chem. 272, 12676-12682.
66. Tao, Q., Backer, M. V., Backer, J. M., and Terman, B. I. (2001) Kinase insert domain receptor (kdr) extracellular immunoglobulin-like domains 4-7 contain structural features that block receptor dimerization and vascular endothelial growth factor-induced signaling. J. Biol. Chem. 276, 21916-21923.
67. Uren, A., Yu, J. C., Karcaaltincaba, M., Pierce, J. H., and Heidaran, M. A. (1997) Oncogenic activation of the alphaPDGFR defines a domain that negatively regulates receptor dimerization. Oncogene 14, 157-162.
68. Lofts, F. J., Hurst, H. C., Sternberg, M. J., and Gullick, W. J. (1993) Specific short transmembrane sequences can inhibit transformation by the mutant neu growth factor receptor in vitro and in vivo. Oncogene 8, 2813-2820.
69. Smith, S. O., Smith, C. S., and Bormann, B. J. (1996) Strong hydrogen bonding interactions involving a buried glutamic acid in the transmembrane sequence of the neu/erbB-2 receptor. Nat. Struct. Biol. 3, 252-258.
70. Gullick, W. J., Bottomley, A. C., Lofts, F. J., Doak, D. G., Mulvey, D., Newman, R., Crumpton, M. J., Sternberg, M. J., and Campbell, I. D. (1992) Three dimensional structure of the transmembrane region of the proto-oncogenic and oncogenic forms of the neu protein. EMBO J. 11, 43-48.
71. Bell, C. A., Tynan, J. A., Hart, K. C., Meyer, A. N., Robertson, S. C., and Donoghue, D. J. (2000) Rotational coupling of the transmembrane and kinase domains of the neu receptor tyrosine kinase. Mol. Biol. Cell 11, 3589-3599.
72. Moriki, T., Maruyama, H., and Maruyama, I. N. (2001) Activation of preformed EGF receptor dimers by ligand-induced rotation of the transmembrane domain. J. Mol. Biol. 311, 1011-1026.
73. Chen, L. I., Webster, M. K., Meyer, A. N., and Donoghue, D. J. (1997) Transmembrane domain sequence requirements for activation of the p185c-neu receptor tyrosine kinase. J. Cell Biol. 137, 619-631.
74. Mattoon, D., Gupta, K., Doyon, J., Loll, P. J., and DiMaio, D. (2001) Identification of the transmembrane dimer interface of the bovine papillomavirus E5 protein. Oncogene 20, 3824-3834.
75. DiMaio, D., Lai, C. C., and Mattoon, D. (2000) The platelet-derived growth factor beta receptor as a target of the bovine papillomavirus E5 protein. Cytokine Growth Factor Rev. 11, 283-293.
76. Meyer, A. N., Xu, Y. F., Webster, M. K., Smith, A. E., and Donoghue, D. J. (1994) Cellular transformation by a transmembrane peptide: structural requirements for the bovine papillomavirus E5 oncoprotein. Proc. Natl. Acad. Sci. USA 91, 4634-4638.
77. Crooks, D., Kil, S. J., McCaffery, J. M., and Carlin, C. (2000) E3-13.7 integral membrane proteins encoded by human adenoviruses alter epidermal growth factor receptor trafficking by interacting directly with receptors in early endosomes. Mol. Biol. Cell 11, 3559-3572.
78. Bennasroune, A., Fickova, M., Gardin, A., Dirrig-Grosch, S., Aunis, D., Cremel, G., and Hubert, P. (2004) Transmembrane peptides as inhibitors of ErbB receptor signaling. Mol. Biol. Cell 15, 3464-3474.
79. Brown, R. J., Adams, J. J., Pelekanos, R. A., Wan, Y., McKinstry, W. J., Palethorpe, K., Seeber, R. M., Monks, T. A., Eidne, K. A., Parker, M. W., and Waters, M. J. (2005) Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat. Struct. Mol. Biol. 12, 814-821.
80. Rahimi, N., Dayanir, V., and Lashkari, K. (2000) Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells. J. Biol. Chem. 275, 16986-16992.
81. Davis, T. L., Walker, J. R., Loppnau, P., Butler-Cole, C., lali-Hassani, A., and Dhe-Paganon, S. (2008) Autoregulation by the juxtamembrane region of the human ephrin receptor tyrosine kinase A3 (EphA3). Structure 16, 873-884.
82. Craddock, B. P., Cotter, C., and Miller, W. T. (2007) Autoinhibition of the insulin-like growth factor I receptor by the juxtamembrane region. FEBS Lett 581, 3235-3240.
83. Zou, J., Wang, Y. D., Ma, F. X., Xiang, M. L., Shi, B., Wei, Y. Q., and Yang, S. Y. (2008) Detailed conformational dynamics of juxtamembrane region and activation loop in c-Kit kinase activation process. Proteins 72, 323-332.
84. Chan, P. M., Ilangumaran, S., La, R. J., Chakrabartty, A., and Rottapel, R. (2003) Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region. Mol. Cell Biol. 23, 3067-3078.
85. Casteran, N., De Sepulveda, P., Beslu, N., Aoubala, M., Letard, S., Lecocq, E., Rottapel, R., and Dubreuil, P. (2003) Signal transduction by several KIT juxtamembrane domain mutations. Oncogene 22, 4710-4722.
86. Gille, H., Kowalski, J., Yu, L., Chen, H., Pisabarro, M. T., Davis, S. T., and Ferrara, N. (2000) A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 30-kinase activation and endothelial cell migration. EMBO J. 19, 4064-4073.
87. McTigue, M. A., Wickersham, J. A., Pinko, C., Showalter, R. E., Parast, C. V., Tempczyk, R. A., Gehring, M. R., Mroczkowski, B., Kan, C. C., Villafranca, J. E., and Appelt, K. (1999) Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis. Structure 7, 319-330.
88. Hubbard, S. R. (2004) Juxtamembrane autoinhibition in receptor tyrosine kinases. Nat. Rev. Mol. Cell Biol. 5, 464-471.
89. Wybenga-Groot, L. E., Baskin, B., Ong, S. H., Tong, J., Pawson, T., and Sicheri, F. (2001) Structural basis for autoinhibition of the Ephb2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region. Cell 106, 745-757.
90. Walter, M., Lucet, I. S., Patel, O., Broughton, S. E., Bamert, R., Williams, N. K., Fantino, E., Wilks, A. F., and Rossjohn, J. (2007) The 2.7 a crystal structure of the autoinhibited human c-Fms kinase domain. J. Mol. Biol. 367, 839-847.
91. Zhang, X., Pickin, K. A., Bose, R., Jura, N., Cole, P. A., and Kuriyan, J. (2007) Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature 450, 741-744.
92. Zhang, X., Gureasko, J., Shen, K., Cole, P. A., and Kuriyan, J. (2006) An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125, 1137-1149.
93. Pellicena, P. and Kuriyan, J. (2006) Protein-protein interactions in the allosteric regulation of protein kinases. Curr. Opin. Struct. Biol. 16, 702-709.
94. Kawamura, H., Li, X., Goishi, K., van Meeteren, L. A., Jakobsson, L., Cebe-Suarez, S., Shimizu, A., Edholm, D., Ballmer-Hofer, K., Kjellen, L., Klagsbrun, M., and Claesson-Welsh, L. (2008) Neuropilin-1 in regulation of VEGF-induced activation of p38MAPK and endothelial cell organization. Blood 112, 3638-3649.
95. Cébe-Suarez, S., Pieren, M., Cariolato, L., Arn, S., Hoffmann, U., Bogucki, A., Manlius, C., Wood, J., and Ballmer-Hofer, K. (2006) A VEGF-a splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. Cell Mol. Life Sci. 63, 2067-2077.
96. Kawamura, H., Li, X., Harper, S. J., Bates, D. O., and Claesson-Welsh, L. (2008) Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity. Cancer Res. 68, 4683-4692.